Month: April 2026

Trump Threatens to Fire Powell, Raising Questions About Fed Independence

Posted on by [email protected]

President Donald Trump escalated his criticism of Federal Reserve Chair Jerome Powell on Wednesday, stating he would “have to fire” Powell if he does not step down when his term as Fed Chair expires on May 15.

The remarks intensify tensions between the White House and the Federal Reserve and introduce new uncertainty around the Fed leadership transition, a key issue for investors closely watching interest rates, inflation policy, and central bank independence.

Fed Leadership Transition Faces Uncertainty

While Powell’s term as Chair ends next month, his position as a member of the Federal Reserve Board extends through 2028. If a successor is not confirmed in time, Powell has said he would remain as interim chair (chair pro tem)—a move consistent with historical precedent.

However, Trump’s comments suggest he may attempt to remove Powell outright, potentially setting up a legal and political battle over control of the central bank.

Trump’s preferred nominee, former Fed governor Kevin Warsh, is scheduled to appear before the Senate Banking Committee next week. But his confirmation faces obstacles. Senator Thom Tillis has indicated he will block Warsh’s nomination unless a Justice Department investigation into Powell is dropped, leaving the nomination short of the votes needed to advance.

This raises the risk of a delayed or contested Fed leadership transition, a scenario that could unsettle financial markets.

Can a President Fire the Fed Chair?

The situation highlights a key legal question: Can a president remove a Federal Reserve Chair?

Under the Federal Reserve Act, board members can be removed “for cause,” generally defined as inefficiency, neglect of duty, or malfeasance. However, the law does not clearly address whether policy disagreements—such as disputes over interest rate decisions—qualify as sufficient cause.

Any attempt to remove Powell without clear legal justification would likely face court challenges and could have significant implications for Federal Reserve independence, a cornerstone of U.S. monetary policy.

DOJ Investigation Adds Another Layer

The Trump administration has pointed to a Justice Department investigation into cost overruns tied to the Federal Reserve’s headquarters renovation as justification for increased scrutiny.

Although a federal judge recently invalidated key subpoenas—weakening the probe—the case is expected to continue through appeals. Powell has stated he intends to remain on the Board until the investigation is fully resolved, signaling he is unlikely to step aside voluntarily.

Market Impact: Why Investors Should Pay Attention

For investors, the situation introduces several risks:

  • Monetary policy uncertainty: Leadership instability at the Fed could cloud the outlook for interest rate decisions
  • Market volatility: Treasury yields and equities may react to perceived political pressure on the Fed
  • Credibility risk: Any erosion of Fed independence could impact inflation expectations and increase risk premiums

Markets are particularly sensitive to signals from the Federal Reserve, and any disruption in leadership could amplify volatility across asset classes.

What to Watch

In the coming weeks, investors should monitor:

  • Kevin Warsh’s Senate confirmation process
  • Legal developments surrounding Powell’s status
  • Updates on the DOJ investigation
  • Movements in Treasury yields and rate expectations

Bottom Line

Trump’s threat to fire Powell underscores rising political pressure on the Federal Reserve at a critical moment for monetary policy.

Whether the situation leads to a legal battle or a smooth transition, the outcome will play a key role in shaping interest rate policy, market stability, and investor confidence in the months ahead.

SPACtrac Report A Paradise Acquisition Corp. (APAD) – Redefining The Future of Sports, Media, and Performance Health

Posted on by [email protected]


Wednesday, April 15, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A new level of competition. Enhanced Group Inc. is an emerging sports, media, and consumer health company seeking to go public via a SPAC merger with A Paradise Acquisition Corp. (APAD). The company is pioneering the “Enhanced Games,” a new athletic competition model that allows medically supervised performance enhancement, while simultaneously building a direct-to-consumer health platform. Its integrated ecosystem combines live events, clinical research, and subscription-based wellness products.

Large market opportunity. Enhanced operates across several high-growth sectors, including telehealth, personalized nutrition, and live sports media, all of which are undergoing structural transformation. Telehealth and performance optimization markets are expanding rapidly due to consumer demand for convenience and personalization, while live sports remain one of the most valuable forms of real-time content globally. These converging trends create a favorable backdrop for new, digitally native platforms that can capture attention and monetize engagement.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Lands An Important European Hospitality Partnership

Posted on by [email protected]


Wednesday, April 15, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

SKYX Secures Strategic European Partnership with Group OTT. SKYX announced a strategic agreement with European developer Jean-François Ott, founder of Group OTT, to deploy its technologies across hotels and buildings. The partnership designates SKYX’s smart ceiling platform as a brand standard across both new and existing assets. This marks a significant step in positioning SKYX as a core infrastructure provider rather than a product vendor.

Agreement Targets Deployment Across 250+ Projects in the Pipeline, Marking a Key Step Toward International Expansion and Platform Standardization. Group OTT brings a track record of over 250 completed projects valued at more than $4 billion across Europe. The agreement enables potential integration of SKYX technologies across a broad pipeline of hospitality, residential, and commercial developments. This provides SKYX with a scalable entry point into the European market and strengthens its standardization thesis.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – Preliminary Q1 2026 Net Sales Expected to Exceed Annual Guidance Run-rate

Posted on by [email protected]


Wednesday, April 15, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Preliminary 1Q26 Revenue. Last night, NN announced that its preliminary Q1 2026 net sales results are expected to demonstrate growth versus the prior year and the Company’s forecast. The Company is maintaining its guidance range on net sales, expecting results to come in toward the top half of its original guidance range of $445 to $465  million.

Positive Momentum on New Business Too. Notably, the New Business program also delivered strong results in Q1. The Company was awarded approximately $43  million of new awards at peak annual sales, centered on the  Electric Grid and Data Center markets. With the strength of NN’s new business wins in Q1 and a strong start in Q2, the Company is raising its full-year guidance range, now expecting new business wins to fall within the range of $80 to $90 million in 2026, up from a prior $70 to $80  million range.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – Sale/Leaseback; Continuing Positive Class 8 Orders

Posted on by [email protected]


Wednesday, April 15, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Sale/Leaseback. Commercial Vehicle Group has completed a sale-leaseback transaction for its manufacturing facility in Vonore, Tennessee, which generated $16 million in proceeds. The Company used the net proceeds from the transaction to prepay a portion of its existing term loan facility, thereby reducing the Company’s leverage profile.

Leverage. At the end of 2025, CVG had net debt of $73.1 million, representing a 4.1x net leverage ratio on 2025 adjusted EBITDA. CVG’s near-term focus remains on cash generation and lowering debt levels. Following this transaction, we believe CVG is even better positioned to drive future growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Obsidian Therapeutics Goes Public Through Galera Merger, Lands $350 Million to Fuel Cell Therapy Pipeline

Posted on by [email protected]

A microcap biotech is getting a new identity — and $350 million to go with it.

Galera Therapeutics (OTC: GRTX) and privately-held Obsidian Therapeutics announced today they have entered into a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Obsidian Therapeutics and plans to trade on Nasdaq under the ticker symbol OBX.

For Galera shareholders, this is a lifeline. The stock was trading at less than five cents on the OTC markets heading into this announcement. For Obsidian, it’s a calculated path to the public markets — using Galera as a vehicle to access Nasdaq without a traditional IPO.

The Deal Structure

Under the merger agreement, Galera will merge into a subsidiary of the new parent company, Gazelle Parent, Inc., while Obsidian simultaneously merges into a separate subsidiary — with both surviving as wholly owned subsidiaries of the combined parent.

Concurrent with the merger, the companies secured commitments for a private placement financing expected to generate $350 million in gross proceeds. That’s a substantial war chest for a clinical-stage biotech, and signals serious institutional conviction in Obsidian’s pipeline.

The ownership breakdown tells the real story of who’s driving this combination: pre-merger equityholders of Obsidian are expected to own approximately 53.2% of the combined company, PIPE investors approximately 45%, and Galera’s legacy shareholders approximately 1.8%. Galera’s existing stockholders are essentially getting a small equity stake in a well-funded new entity rather than facing dissolution.

Who’s Backing It

Investors in the private placement include Balyasny Asset Management, Caligan Partners, Eventide Asset Management, Nantahala Capital, Octagon Capital, Redmile, Spruce Street Capital, and Trails Edge Capital Partners. That’s a roster of credible, healthcare-focused institutional names — not speculative money.

What Obsidian Actually Does

Obsidian focuses on engineered cell and gene therapies targeting unmet medical needs, while Galera had concentrated on treatments for radiation-induced toxicities. The combined company’s primary asset is OBX-115, a TIL (tumor-infiltrating lymphocyte) cell therapy. The company expects Phase 1 NSCLC data in the first half of 2027 and topline data from a melanoma registration-enabling trial by year-end 2027, supported by the merged company’s expanded cash runway.

TIL cell therapy is an emerging but compelling approach in oncology — it extracts a patient’s own immune cells from a tumor, engineers them, and reinfuses them to fight cancer. The space has attracted significant Big Pharma attention as cell therapy continues to mature beyond CAR-T into broader tumor types.

The Bigger Picture

This transaction is a textbook example of a structure the small-cap biotech world relies on — a reverse merger into a public shell paired with a concurrent PIPE to fund the surviving entity’s operations. It avoids the cost and volatility of a traditional IPO while still achieving a Nasdaq listing and fresh capital.

Closing requires approval from Galera and Obsidian stockholders, effectiveness of a Form S-4 registration statement, receipt of the approximately $350 million in private placement proceeds, and Nasdaq approval for the new parent’s listing.

For small-cap investors, the question now is whether OBX can justify that institutional confidence when the clinical data arrives in 2027.

Release – Preliminary Q1 2026 Net Sales Expected to Exceed Annual Guidance Run-rate

Posted on by [email protected]

Research News and Market Data on NNBR

PDF VersionNN Increases its 2026 New Business Wins guidance range to $80 to $90 million; Q1 wins heavily concentrated in Electric Grid and Data Center markets

CHARLOTTE, N.C., April 14, 2026 (GLOBE NEWSWIRE) — NN, Inc. (“NN” or the “Company”) (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies with six sigma quality, today announced that its preliminary Q1 2026 net sales results are expected to demonstrate growth versus the prior year and the Company’s forecast.

The New Business program also delivered strong results in Q1. The Company was awarded approximately $43 million of new awards at peak annual sales, centered on the Electric Grid and Data Center markets. Notably, these awards continue NN’s strong recent momentum as the Company re-positions its overall portfolio in key secular high-growth markets and away from commodity automotive markets. With the strength of NN’s new business wins in Q1 and a strong start in Q2, the Company is raising its full-year guidance range, now expecting new business wins to fall within the range of $80 million to $90 million in 2026.

The launch of more than 60 new programs has resulted in a shippable backlog as orders outpaced production during the quarter. These newly launched programs and traction in key end markets are positioning NN to drive strong net sales growth through 2026 and beyond. NN is maintaining its guidance range on net sales, expecting results to come in toward the top half of its original guidance range of $445 million to $465 million.

Harold Bevis, Chief Executive Officer and President of NN, Inc., commented, “NN’s sales are growing as expected and trending towards the high end of our previously guided range. Electric Grid, Data Center, Defense, and Electronics end markets are doing well, while global auto is stabilizing. Additionally, we are underway with industrializing a large portion of our previously awarded growth programs. This is expected to support our sales growth targets for 2026 and beyond. These sales are being produced through a lower cost operating model that is strengthening margins. With the large value of Electric Grid and Data Center new awards in Q1, we are increasing our guidance in this area to approximately $80 to $90 million of expected new sales wins secured during 2026.”

“We are targeting strong sales growth in 2026 and beyond as well as increasing the amount and share of non-commodity auto business at the Company. Overall, our end markets and customers are healthy while global auto undergoes changes. We are currently running ahead of both our 2026 and long-term goals. We look forward to providing more information on the performance of the business when we release Q1 2026 earnings, which is planned for May 6, 2026.”

The Company is finalizing its financial results for the quarter ended March 31, 2026. The above information is based on preliminary information and management’s estimates for the quarter ended March 31, 2026, and is subject to the Company’s financial statement closing procedures.

ABOUT NN’S GROWTH PROGRAM

NN is underway with an intentional program to grow sales, improve its profit profile, and reposition its end-market exposure. NN is pursuing several target markets that (1) require products that deliver safety critical functionality at scale; (2) fit the Company’s engineering and manufacturing platform; and (3) allow for higher, accretive margins due to delivering higher value. The targeted end-markets include:

  • High-value auto parts – NN’s current #1 end market
  • Electric grid and data center parts – NN’s current #2 end market, on a plan to become NN’s #1 end market
  • Defense, weapons, and electronic parts
  • Medical equipment parts

ABOUT NN

NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and China. For more information about the Company and its products, please visit www.nninc.com.

Forward-Looking Statements

This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding NN’s expect Q1 2026 net sales and expected new business wins and net sales for 2026 and other statements that are not historical facts. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “growth,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project”, “trajectory” or other similar words, phrases or expressions. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, those related to the preliminary nature of NN’s quarter ended March 31, 2026 financial information, which is subject to completion of normal quarter-ended accounting procedures and closing adjustments; the assumptions underlying NN’s new business wins guidance for fiscal 2026, general economic conditions and economic conditions in the industrial sector; material changes in the costs and availability of raw materials; the level of our indebtedness; our ability to secure, maintain or enforce patents or other appropriate protections for our intellectual property; and cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor Relations: 
Joseph Caminiti or Abe Plimpton
[email protected]  
312-445-2870 

Primary Logo

Source: NN, Inc.

Release – GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market

Posted on by [email protected]

Research News and Market Data on GOVX

Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide

ATLANTA, GA, April 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today highlighted the urgent challenges caused by the supply-constrained, global orthopoxvirus vaccine market and outlined the strategic positioning of its GEO-MVA vaccine candidate to address the limited supply and increasing global demand.

A Procurement-Driven Market with Recurring Global Demand

The global market for vaccines targeting mpox and smallpox (orthopoxviruses) has evolved into a recurring, procurement-driven market supported by:

  • National stockpile programs across the United States, Europe and allied countries
  • Ongoing purchasing by global health organizations and regional agencies
  • Outbreak-driven surge demand tied to periodic global transmission events

Recent mpox outbreaks across multiple continents, including the emergence of more virulent strains, have reinforced the need for sustained vaccine supply beyond emergency response cycles.

Single-Supplier Market Structure and Limited Surge Capacity

The current global supply of MVA vaccines, the preferred vaccine for orthopoxvirus infections due to their recognized safety for use in vulnerable populations, is concentrated with a single commercial supplier.

This market structure has contributed to:

  • Limited surge capacity during outbreaks
  • Repeated depletion of government stockpiles
  • Increased focus on supply chain resilience and diversification

As a result, governments and public health agencies are increasingly prioritizing:

  • Establishment of additional sources of MVA vaccine supply
  • Expansion of domestic and allied manufacturing capacity
  • Reduced dependence on single-source providers for critical countermeasures

An Established Market Measured in Hundreds of Millions Annually

Public disclosures and procurement activity indicate that the mpox/smallpox vaccine market:

  • Has generated hundreds of millions of dollars in annual procurement in recent years
  • Includes multiyear purchasing frameworks and forward-looking supply agreements
  • Is supported by both baseline stockpiling demand and outbreak-driven purchasing cycles

GeoVax believes these dynamics support a durable and expanding global market, rather than a one-time, pandemic-driven market opportunity.

GEO-MVA Positioned as a Second-Source MVA Vaccine Candidate

GeoVax’s GEO-MVA vaccine candidate is being developed to address the current supply-demand imbalance. The Company believes GEO-MVA is positioned as a potential second-source MVA vaccine, with key attributes including:

  • Leverages the established MVA platform, widely used for immunocompromised and high-risk populations
  • A defined regulatory pathway, based on immuno-bridging, to an approved MVA vaccine
  • Late-stage development readiness, with Phase 3 initiation planned during 2026

GeoVax believes GEO-MVA has the potential to support:

  • National stockpile replenishment programs
  • Global outbreak response efforts
  • Long-term preparedness and biodefense strategies

Alignment with Public Health and Biodefense Priorities

The mpox/smallpox vaccine market is increasingly shaped by the intersection of:

  • Public health preparedness, driven by recurring mpox outbreaks and evolving viral threats
  • National security and biodefense priorities, including protection against biological threats

Recent U.S. and international policy initiatives have emphasized:

  • Strengthening biosecurity infrastructure
  • Expanding domestic manufacturing capabilities
  • Ensuring reliable access to critical medical countermeasures

GeoVax believes GEO-MVA is positioned for both civilian and biodefense procurement channels.

Development Timeline Synchronized with Procurement Cycles

GeoVax believes its planned development timeline for GEO-MVA corresponds with:

  • Anticipated stockpile replenishment cycles following recent depletion
  • Continued global procurement activity driven by outbreak preparedness
  • Increasing policy emphasis on supply diversification initiatives

David Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “The mpox and smallpox vaccine market is not a future construct, it is an active, procurement-driven market with recurring demand and increasing strategic importance. It is also a market currently defined by supply concentration and limited surge capacity.”

Mr. Dodd added, “We believe that, if approved, GEO-MVA, which is expected to begin a pivotal Phase 3 trial this year, is positioned to enter this market as a second-source MVA vaccine at a time when governments and global health organizations are actively seeking to diversify supply and strengthen preparedness. Our focus is on executing the next phase of development and aligning GEO-MVA with procurement frameworks that support both long-term stockpiling and rapid response capabilities.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected] 

Release – SKYX Signs Strategic Partnership Agreement with Prominent European Hotel & Real Estate Developer, Jean-François Ott, Founder of Group OTT, to Deploy Its Advanced and Smart Electrical Technologies as a Brand Standard Throughout Its Hotels and Buildings

Posted on by [email protected]

Research News and Market Data on SKYX

April 14, 2026 08:45 ET  | Source: SKYX Platforms Corp.

Share

Over the Past 35 Years, Jean-François Ott and Group OTT Have Developed Over 250 Hospitality, Residential, and Commercial Buildings Valued at Over $4 Billion Throughout Europe

SKYX’s Technologies are Expected to Reduce Up to 90% of Time and Cost During Group OTT’s Hotel and Building Renovations and New Builds Across Europe

The Agreement Involves the Integration of SKYX’s Technologies Across Existing and Future Assets of Group OTT

SKYX is Currently in Discussions with Additional Hotel Groups and Owners Regarding Utilization of Its Smart Advanced Time and Cost Saving Game-Changing Technologies for Hotels and Buildings

MIAMI, April 14, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), an award winning highly disruptive advanced and smart home platform technology company with over 100 U.S. and global pending and issued patents and a portfolio of 60 lighting and home décor websites, with a mission to make homes and buildings become advanced-safe-smart instantly as the new standard, today announced its collaboration with prominent European real estate and hotel developer, Jean-François Ott, founder of Group OTT, to deploy SKYX technologies as a brand standard throughout its new and existing buildings and hotels in Europe.

Under this strategic agreement and partnership, the utilization of SKYX’s technologies in Group OTT’s European properties is expected to reduce up to 90% of time and cost during their hotel and building renovations and new builds, while providing the Group advanced and safer properties.

For more than 35 years, France-based Group OTT has developed more than 250 buildings throughout Europe, including hotels, residential, and commercial projects valued at over $4 billion.

Jean-François Ott, Founder of Group OTT, said; “I am very excited to partner with SKYX and bring their advanced and smart technologies into my companies’ existing and upcoming hotels and buildings across Europe. Throughout all these projects, our goal has always been to deploy leading and highly disruptive technologies. By integrating SKYX’s technologies into these properties, we will cut significant time and cost while advancing the lifestyle and safety standards of our hotels and buildings.”

Rani Kohen, Founder and Executive Chairman of SKYX Platforms, said; “We are very excited to be in this strategic partnership with an established and prominent European hotel and real estate developer such as Jean-François Ott and Group OTT. We look forward to collaborating with him and all his companies on their European and global existing and upcoming projects to enhance the value of their properties while creating advanced, smart, and safer hotels and buildings of the future.”

SKYX Offers Group OTT a Structural Innovation at the Core of its Hotels and Buildings

SKYX has developed a patented “smart ceiling” technology designed to transform traditional electrical installations into modular, safe, and intelligent systems. In practical terms, this innovation replaces fixed electrical wiring for ceiling lights, fans, smart tech, and other equipment with an integrated ceiling receptacle system, enabling:

  • simplified and safer installation, with no exposed wiring,
  • significant reductions in installation time and costs,
  • easier maintenance and enhanced modularity, and
  • native integration of connected features (smart, lighting, IoT, etc.).

This approach introduces a paradigm shift in building infrastructure, comparable to the historical emergence of standardized wall outlets.

For more information about Jean-François Ott and Group OTT click here: https://www.groupott.com/

For more information about SKYX click here: www.skyx.com

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contacts:

Jeff Ramson
PCG Advisory
[email protected]

Ronald A. Both
Encore Investor Relations
[email protected]

Release – Greenwich LifeSciences Provides Update on Financing Strategy

Posted on by [email protected]

Research News and Market Data on GLSI

 Download as PDF April 14, 2026 6:00am EDT

STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy.

The Company’s ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for Q1 2026 exceeded the Company’s Q1 2026 cash burn rate, leading to a Q1 2026 cash balance of approximately $10.5 million as of March 31, 2026. The above preliminary financial figures are unaudited and are subject to change following completion of the Company’s financial review for Q1 2026.

About FLAMINGO-01 Open Label Phase III Data

More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

  • In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
  • This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
  • The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

  • 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
  • The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Primary Logo

Source: Greenwich LifeSciences, Inc.

Released April 14, 2026

Amazon’s $11.6 Billion Globalstar Grab Is About More Than Satellites — It’s a Direct Challenge to Starlink’s Dominance

Posted on by [email protected]

Amazon’s acquisition of Globalstar for approximately $11.57 billion — or $90 per share — is one of the most strategically loaded deals of 2026, and it’s a reminder that small-cap companies can sit at the center of the biggest transactions in the market. Globalstar, once a modest satellite operator with a market cap well beneath the radar of most institutional investors, has become the cornerstone of Amazon’s bid to compete directly with Elon Musk’s SpaceX in the rapidly expanding space connectivity market — while simultaneously locking in a critical partnership with Apple.

The Strategic Play

Amazon has been building its satellite internet business — rebranded from Project Kuiper to Leo — for years, but the company has faced significant headwinds. It currently has roughly 240 satellites in orbit compared to Starlink’s fleet of more than 10,000, and it recently had to ask the FCC for an extension on a requirement to deploy approximately 1,600 satellites by July 2026. Acquiring Globalstar addresses a key structural gap: direct-to-device capability.

Globalstar operates around 24 satellites and holds spectrum licenses with global authorizations — assets that are notoriously difficult and time-consuming to obtain independently. Rather than build this foundation from scratch, Amazon is buying it. The company plans to start deploying its own direct-to-device satellite system using these assets by 2028.

The Apple Dimension

Apple’s fingerprints are all over this deal. The iPhone maker took a 20% stake in Globalstar in 2024 through a $1.5 billion investment, primarily to power its Emergency SOS satellite feature. As part of the Amazon acquisition, a separate agreement was struck for Amazon to provide satellite connectivity for current and future iPhones and Apple Watch features — a significant commercial arrangement that effectively makes Amazon a behind-the-scenes infrastructure provider for Apple’s device ecosystem.

This isn’t a minor footnote. It signals that Amazon is positioning Leo not just as a consumer internet service competing with Starlink, but as a B2B infrastructure layer for some of the world’s most widely used consumer devices.

Regulatory Outlook

FCC Chairman Brendan Carr acknowledged the acquisition on Tuesday, describing the agency as open-minded to the deal and noting its potential to create a viable U.S. competitor to SpaceX in direct-to-cell services. The transaction is expected to close in 2027, leaving meaningful time for regulatory review.

Carr’s framing is notable — the FCC has been consistent in its messaging that it wants to encourage competition in the satellite broadband market, not constrain it. Amazon had ironically opposed a SpaceX application before the FCC last month, so the agency’s receptiveness to this deal will be worth monitoring.

What This Means for the Market

Globalstar shareholders will receive either $90 in cash or 0.3210 shares of Amazon common stock per Globalstar share — a structure that reflects Amazon’s confidence in its own equity. For investors watching the satellite and space economy, this deal narrows the competitive field considerably. The race to own low-Earth orbit spectrum and direct-to-device infrastructure is intensifying, and scale is the only real moat.

Amazon just bought itself a meaningful head start. Whether it’s enough to close the gap with Starlink remains the central question for the next decade of space-based connectivity

Snail (SNAL) – Licensing Agreement Raises Cash Flow; Raise Price Target

Posted on by [email protected]


Tuesday, April 14, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Snail Renegotiates ARK License. The amendment lowers fixed licensing costs from $2.0 million to $1.5 million per month, implying  $1.5 million in quarterly savings. The obligation remains in place until the release of ARK 2, preserving near-term cost visibility. The move shows that the company is independently evaluating contracts on a timely basis.

DLC Payment Terms Revised to Reduce Future Cash Obligations. The amendment replaces blanket $5 million DLC payments with a more selective structure, excluding certain content such as DLCs already bundled in ARK: Survival Ascended. This change further moderates future cash outflows tied to the franchise. Improved cash flow generation provides greater flexibility to invest in upcoming titles and franchise development. It also reduces financial risk as the company transitions toward the next major ARK release.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Oncology Institute, Inc. (TOI) – CMS Model Shows Medicare Cost Savings, Supporting Our Investment Thesis

Posted on by [email protected]


Tuesday, April 14, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

TOI Methodology Continues To Improve Medicare Cost Savings. TOI announced new data from the Enhancing Oncology Model (EOM) developed by the Centers for Medicare & Medicaid Services (CMS). Data from CMS shows that during Performance Period 3, the six-month period beginning July 2024, TOI achieved cost savings of $1.8 million, equating to $6,400 per patient-episode. This compares with the Performance Period 2, from January 2024 to June 2024, in which savings were $1.1 million or $3,500 per episode.

TOI Methodology Fits Well With The EOM. The CMS Innovation Center developed the EOM as a total-cost-of-care model to improve cancer care for Medicare Fee-for-Service beneficiaries. It incentivizes oncology practices to deliver coordinated care for patients receiving chemotherapy. The EOM model has identified pharmacy, avoidable acute care, and supportive care as the three main areas for cost reduction and quality-of-care improvements. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.